AURA · Aura Biosciences, Inc.

📣 What AURA Says Is Next

• 2H 2027 · “Clinical Pipeline Across Ocular Oncology Program Preclinical Phase 1 Phase 2 Phase 3 Early Choroidal melanoma Metastases tothe Choroid Cancers of theOcular Surface Topline data from the 15-month primary endpoint remain on track for 2H 2027 DLT, dose-limiting toxicity; MoA, mechanism of action; NMIBC, non-muscle-invasive bladder cancer; SAE, serious adverse event; VLP, virus-like particle.”
  Company press release, Aug 11, 2026 · SEC filing
• first half of 2029 · “Together with disciplined capital allocation, these actions are expected to extend the Company's projected cash runway into the first half of 2029 to support execution of the Phase 3 CoMpass trial, advancement of its additional ocular oncology programs and preparation for potential commercialization.”
  Company press release, Aug 11, 2026 · SEC filing
• second half of 2027 · “Topline data from the 15-month primary endpoint remain on track for the second half of 2027, consistent with previously communicated guidance.”
  Company press release, Aug 11, 2026 · SEC filing

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

💰 Cash Runway & Dilution Risk

AURA reported $323.8M in cash and short-term investments (as of Jun 30, 2026) and used about $31.5M/quarter in operations, an estimated runway of 30.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 30 · Moderate

• Cash runway 31 months
• ATM program on file since Aug 2026 +15
• Shelf registration (S-3, Aug 2026) +10
• Company says cash lasts into the first half of 2029 -15We believe that our existing cash and cash equivalents and marketable securities will enable us to fund our operations into the first half of 2029. 10-Q, Aug 2026
• Share count +67% in a year +20

Recent financing filings on SEC EDGAR:

• Aug 11, 2026 · Shelf registration with ATM program, up to $200M · S-3
• May 5, 2026 · Underwritten offering · 424B5
• May 4, 2026 · Underwritten offering · 424B5
• May 16, 2025 · Underwritten offering · 424B5
• May 15, 2025 · Underwritten offering · 424B5
• Mar 27, 2024 · Shelf registration with ATM program, up to $75M · S-3

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AURA files for a raise →

👥 Who Owns AURA

Share count 103,704,809 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.